Leveraging Programmable CRISPR-Associated Transposases for Next-Generation Genome Engineering
Dr. Sam Sternberg discusses a novel CRISPR-Cas9 system using programmable, RNA-guided transposase, and highlights its implications for kilobase-scale genome engineering in cell and gene therapies.
Cancer Immunotherapy: Viruses, Vaccines, and other Immuno-Oncology Treatments
In this blog post, current cancer immunotherapy treatments are discussed, as well as some future directions for this rapidly developing field.
Essential Bruker NMR Trainings 2023
Join Bruker experts online for 1 hour every month in this essential training program designed for NMR Scientists.
The 3D DILI Model of Success – from Biological Relevance to Industry Application
Dr. Anna Borgström and Dr. Frauke Greve present the latest advancements in hepatic safety assessment using 3D liver spheroids.
#ExpertAnswers: Audrey Dubourg and Gareth Guenigault on the Organ-On-A-Chip Approach
Audrey Dubourg and Gareth Guenigault from CN Bio discuss the value that an organ-on-a-chip approach can bring to drug discovery and development workflows, and how the regulatory landscape is shifting to encourage their widespread adoption.
Industry Insights with Crown Bioscience: Targeting T Cells Within the Cancer-Immunity Cycle
In this episode of Industry Insights, Saskia De Man, PhD, Marrit Putker, PhD, and Pirouz Daftarian, PhD, from Crown Bioscience discuss assays and methods for evaluating T cell therapeutics, including organoids, co-cultures, and high content imaging.
#ExpertAnswers: Ejvind Mørtz on Protein Analysis
Ejvind Mørtz discusses the benefits and applications of mass spectrometry (MS)-based host cell protein (HCP) analysis and why HCP ELISAs are insufficient for documenting product-related impurities.
APS Physiology in Disease Modeling and Drug Development Roundtable
Key opinion leaders in cardiovascular physiology and bioengineering discuss best practices and challenges when modeling cardiomyopathies and other cardiovascular diseases using stem cells, engineered tissues and other novel platforms.
#ExpertAnswers: Andrew Taylor on Drug Metabolism
Andrew Taylor provides an overview of processes by which drugs are metabolized and talks about the importance of drug metabolism and drug-drug interaction studies.
It’s Life, but Not As We Know It: How Predictive Human Organ Models Are Transforming and Reshaping the Efficiency of Drug Discovery
Dr. Audrey Dubourg and Dr. Gareth Guenigault explore the value that an organ-on-a-chip approach can bring to drug discovery and development workflows, and how the regulatory landscape is shifting to encourage their widespread adoption.
Industry Insights with Crown Bioscience: In Vitro Technologies for Studying the Cancer-Immunity Cycle
In this episode of Industry Insights, Rajendra Kumari, PhD, and Gera Goverse, PhD, from Crown Bioscience answer questions about in vivo, in vitro, and ex vivo technologies and methods that can be used for immuno-oncology research along each step of the cancer-immunity cycle.
Rethink your Impurity Analysis Strategy
In this webinar, Dr. Ejvind Mørtz discusses the benefits and applications of mass spectrometry (MS)-based host cell protein (HCP) analysis and why HCP ELISAs are insufficient for documenting product-related impurities. Watch to learn where to apply the assay in a typical process and what you gain from deploying it to your workflow.
Are In Vitro Metabolism and Drug-Drug Interaction Studies Critical for an Investigational New Drug Application?
Andrew G. Taylor, PhD provides an overview of processes by which drugs are metabolized and discusses the importance of drug metabolism and drug-drug interaction studies.
Overcoming Critical Issues in Glioblastoma Multiforme (GBM) Therapeutic Development
This article, originally published on Scientist.com, reviews the current standard of care for glioblastoma multiforme (GBM), challenges in developing accurate preclinical GBM models and effective therapies, and the future of GBM drug discovery.
Intestinal Toxicity Assessment with Patient-Derived Organoids
Dr. Martin Stahl describes the use of patient-derived intestinal organoids to assess the toxicity of potential therapeutic compounds and study barrier function in a human-specific model system.
Combination Therapy for Cancer Treatment
The combination of anti-cancer drugs, or combination therapy, has been hailed as a “cornerstone of cancer therapy” since it targets key pathways synergistically, thereby enhancing efficacy compared to monotherapies. This blog takes a look at a recent publication in Nature, which reported the effects of 2025 pairwise drug combinations in breast, colon, and pancreatic cell lines.
#ExpertAnswers: Peter Ansell and Marian Navratil on Gene Expression Profiling
Peter Ansell and Dr. Marian Navratil discuss the use of novel RNA-based gene expression profiling technologies for clinical and preclinical oncology research.
Discovering a Novel Therapy for Urinary Tract Infections
Originally published on Scientist.com, this article provides an overview of antimicrobial therapies, antimicrobial resistance, and advantages of in silico methods for drug discovery.
Inhalable COVID-19 Vaccines: Recent Findings and Breakthroughs
Given that SARS-CoV-2 is primarily transmitted through respiratory droplets, with respiratory mucosa being the main viral entry route, is intramuscular administration the most effective vaccine delivery method to fight COVID-19? In this blog post, we have reviewed one recent study that reported the design and preclinical testing of an inhalable, exosome-based COVID-19 vaccine.
Cell Painting: The Colorful Future of Drug Discovery
A panel Q&A originally published on Scientist.com that introduces cell painting and highlights its value in preclinical and early drug discovery programs.
#ExpertAnswers: Edward LeCluyse and Paul Gallant on a Novel Hepatic Triculture System
Edward LeCluyse and Paul Gallant discuss their novel all-human hepatic triculture system including its benefits and applications.
Alzheimer’s Disease: Recent Research & Therapeutic Advances
A review of Alzheimer's disease pathology, conventional treatments and their limitations, as well as emerging and potential therapies including monoclonal antibodies, metabolic therapies, and stem cell therapies.
Integration of the HTG Transcriptome Panel into Preclinical and Clinical Programs to Drive Precision Medicine Research
Dr. Peter Ansell discusses the use of novel RNA-based gene expression profiling methods for clinical and preclinical oncology research.
A Novel, All-Human Hepatic Triculture System
Join Edward LeCluyse and Paul Gallant as they offer insight into a novel, all-human hepatic triculture and how this unique system addresses the need for a convenient and human-relevant long-term hepatic culture.
#ExpertAnswers: Bin Xie on Drug Development for Immuno-Oncology
Bin Xie discusses the current immuno-oncology drug development landscape, different humanized mouse models available for drug testing, and the investigation of potential mechanisms via imaging mass cytometry.
